Summary
AbbVie Inc. (ABBV) filed an 8-K on July 27, 2023, primarily to furnish its press release detailing its financial results for the second quarter ended June 30, 2023. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release (Exhibit 99.1) for this crucial information. Investors should review the furnished press release for comprehensive details on AbbVie's performance during the quarter, including revenue, earnings per share, and any forward-looking guidance provided.
Key Highlights
- 1AbbVie Inc. announced its second quarter 2023 financial results via a press release furnished with the 8-K filing.
- 2The 8-K filing's primary purpose is to provide public access to the Q2 2023 earnings press release.
- 3Investors seeking detailed financial performance data for the quarter ending June 30, 2023, must refer to Exhibit 99.1.
- 4The filing confirms the date of the announcement of Q2 2023 results as July 27, 2023.
- 5No new material events beyond the Q2 earnings announcement are detailed in the 8-K itself.